Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 249Carcinoma, Non-Small-Cell Lung 227Prostatic Neoplasms 117Neoplasms 106Multiple Myeloma 91Neoplasm Metastasis 76Colorectal Neoplasms 74Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 67Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 47Melanoma 46Leukemia, Lymphocytic, Chronic, B-Cell 44Carcinoma, Renal Cell 44Urinary Bladder Neoplasms 41Triple Negative Breast Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Recurrence 41Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Lymphoma, Follicular 35Nasopharyngeal Carcinoma 34Head and Neck Neoplasms 33Pancreatic Neoplasms 32Rectal Neoplasms 31Lymphoma, Large B-Cell, Diffuse 30Colonic Neoplasms 29

Interventions

ravulizumab 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Optic Neuritis × 1 year × Clear all
NCT07100990 2026-05-05

TIMELY-PLEX

Mayo Clinic

Phase 3 Recruiting
382 enrolled

Myelitis, Myelitis, Transverse, Optic Neuritis

NCT04201262 2025-10-14

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
58 enrolled 19 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡